Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDS

Expert Opinion on Investigational Drugs

Volumn 21, Issue 4, 2012, Pages 489-500

  Uckun, Fatih M ^a,b,c   Cahn, Pedro ^d,e,f   Qazi, Sanjive ^a,c   D'Cruz, Osmond ^a,c  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Paradigm Pharmaceuticals   (United States)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^e HOSPITAL JUAN A FERNÁNDEZ   (Argentina)

^f FUNDACIÓN HUÉSPED   (Argentina)

Author keywords

AIDS; Human immunodeficiency virus 1; Nucleoside reverse transcriptase inhibitor; Pre exposure prophylaxis; Reverse transcriptase

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; STAMPIDINE; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NONHUMAN; REVIEW; SINGLE DRUG DOSE;

ANIMALS; ANTI-RETROVIRAL AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DIDEOXYNUCLEOTIDES; DRUG EVALUATION, PRECLINICAL; HIV INFECTIONS; HIV-1; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STAVUDINE; THYMIDINE MONOPHOSPHATE;

EID: 84858187453     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.664635     Document Type: Review

References (95)

1. The AIDS Institute Global Fact Sheet. Available from: http://www. theaidsinstitute.org/sites/default/files/attachments/THE%20AIDS% 20INSTITUTE%20Global%20Fact% 20Sheet.pdf
2. Richman DD, Margolis DM, Delaney M, et al. The challenge of finding a cure for HIV infection. Science 2009;323:1304-7
3. Howell AL, Asin SN, Yeaman GR, Wira CR. HIV-1 infection of the female reproductive tract. Curr HIV/AIDS Rep 2005;2:35-8
4. Gurney KB, Elliott J, Nassanian H, et al. Binding and transfer of human immunodeficiency virus by DC-SIGN+ cells in human rectal mucosa. J Virol 2005;79:5762-73 (Pubitemid 40548245)
5. Kreiss J, Ngugi E, Holmes K, et al. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 1992;268:477-82
6. Roddy RE, Zekeng L, Ryan KA, et al. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med 1998;339:504-10 (Pubitemid 28384883)
7. Richardson BA, Lavreys L, Martin HL Jr, et al. Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial. Sex Transm Dis 2001;8:394-400 (Pubitemid 32613682)
8. Van Damme L, Ramjee G, Alary M, COL-1492 Study Group. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002;360:971-7 (Pubitemid 35284107)
9. Peterson L, Nanda K, Opoku BK, et al. SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo controlled trial in Ghana. PLoS ONE 2007;2:e1312
10. Feldblum PJ, Adeiga A, Bakare R, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 2008;3:e1474
11. Halpern V, Ogunsola F, Obunge O, et al. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One 2008;3:e3784
12. Van Damme L, Govinden R, Mirembe F, CS Study Group. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008;359:463-72
13. Family Health International (FHI). FHI closes phase III trial of cellulose sulfate for HIV prevention; Research Triangle Park, NC: FHI, January 31, 2007. Available from: http://www.fhi.org/en/AboutFHI/Media/Releases/res-CS- Nigeria.htm
14. CONRAD. Phase III trials of cellulose sulfate microbicide for HIV prevention closed [press release]. 2007. Available from: http://www.medi calnewstoday. com/articles/62310.php
15. Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1977-87
16. McCormack S, Ramjee G, Kamali A, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase III, randomised, double-blind, parallel-group trial. Lancet 2010;376:1329-37
17. Abdool Karim S, Coletti A, Richardson B, HIV Prevention Trials Network (HPTN) 035 Study Team. Safety and effectiveness of vaginal microbicides BufferGel and 0.5% PRO 2000/5 gel for the prevention of HIV infection in women: results of the HPTN 035 trial. AIDS 2011;25:957-66
18. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-6 (Pubitemid 26097216)
19. Cohen MS, Hosseinipour M, Kashuba AD, Butera S. Use of antiretroviral drugs to prevent sexual transmission of HIV. In: Remington JS, Swartz MN, editors. Current Clinical Topics in Infectious Diseases. Volume 22 Blackwell Science; Cambridge, MA: 2002. p. 214-51
20. AVERT (AIDS Education & Research Trust). Post exposure prophylaxis and pre-exposure prophylaxis. Available from: http://www.avert.org/pep-prep-hiv. htm
21. CDC. Pre-exposure prophyxaxis (PrEP), February 21, 2011. Available from: http://www.cdc.gov/hiv/prep/
22. AIDS Vaccine Advocacy Coalition. Global advocacy for HIV prevention. Ongoing PrEP trials. Available from: http://www.avac.org/ht/d/sp/i/3507/pid/3507
23. Naswa S, Marfatia YS. Pre-exposure prophylaxis of HIV. Indian J Sex Transm Dis 2011;32:1-8
24. Mayer KH, Venkatesh KK. Chemoprophylaxis for HIV prevention: new opportunities and new questions. J Acquir Immune Defic Syndr 2010;55(Suppl 2):S122-7
25. Garcia-Lerma JG, Paxton L, Kilmarx PH, Heneine W. Oral pre-exposure prophylaxis for HIV prevention. Trends Pharmacol Sci 2010;31:74-81
26. Lampe MA, Smith DK, Anderson GJ, et al. Achieving safe conception in HIV-discordant couples: the potential role of oral preexposure prophylaxis (PrEP) in the United States. Am J Obstet Gynecol 2011;204:488; e1-8
27. Kelesidis T, Landovitz RJ. Preexposure prophylaxis for HIV prevention. Curr HIV/AIDS Rep 2011;8:94-103
28. De Clercq E. Pre-exposure chemoprophylaxis of HIV infection: quo vadis? Biochem Pharmacol 2012;83:567-73
29. Tsai C-C, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine. Science 1995;270:1197-8
30. Subbarao S, Otten RA, Ramos A, et al. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis 2006;194:904-11 (Pubitemid 44454075)
31. Van Rompay KK, Kearney BP, Sexton JJ, et al. Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus. J Acquir Immune Defic Syndr 2006;43:6-14 (Pubitemid 44306481)
32. Garcia-Lerma JG, Otten RA, Qari SH, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 2008;5:e28
33. Denton PW, Estes JD, Sun Z, et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 2008;5:e16
34. Denton PW, Krisko JF, Powell DA, et al. Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS One 2010;5:e8829
35. Neff CP, Ndolo T, Tandon A, et al. Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model. PLoS One 2010;5:e15257
36. CDC Update: TDF2 study of pre-exposure prophylaxis (PrEP) among heterosexual men and women in Botswana: key facts. Available from: http://www.cdc.gov/hiv/prep/pdf/TDF2factsheet.pdf
37. University of Washington Partners PrEP Study update: Pivotal study finds that HIV medications are highly effective as prophylaxis against HIV infection in men and women in Africa. July 13, 2011. Available from: http://depts. washington. edu/astda/resources/PrEP-PressRelease-UW-13Jul2011.pdf
38. Baeten J, Celum C. on behalf of the Partners PrEP Study Team. Antiretroviral preexposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP Study [abstract MOAX0106]. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Rome, Italy; 2011
39. Celum C, Baeten JM. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence. Curr Opin Infect Dis 2012;25:51-7
40. CDC. Results of FEM-PrEP clinical trial examining pre-exposure prophylaxis (PrEP) for HIV prevention among heterosexual women (April 18, 2011). Available from: http://www.cdc.gov/hiv/prep/femprep.htm
41. FHI 360: FEM-PrEP June 2011 Update: FEM-PrEP study will be highly unlikely to demonstrate Truvada's effectiveness in preventing HIV infection in the study population. Available from: http://www. fhi360.org/NR/rdonlyres/ erj6hevouwvddigjldvcca6tvtybfolh 4nedyfeo4yz2i7la53jknim6ex42bme2 rvyq6zfzovyrkb/FEMPrEPFactSheetJune2011.pdf
42. Grant RM, Lama JR, Anderson PL, iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-99
43. IAS 2011: Final iPrEX analysis confirms PrEP effectiveness for gay men; 29 July 2011. Available from: http://www. hivandhepatitis.com/hiv-prevention/ hivprep/3113-ias-2011-final-iprex-analysisconfirms-prep-effectiveness
44. Liegler T, Abdel-Mohsen M, Atchison R. and iPrEx Study Team. Drug resistance and minor drug resistant variants in iPrEx [abstract 97LB]. 18th Conference on Retroviruses and Opportunistic Infections (CROI); Boston, MA; 2011
45. Anderson PL, Kiser JJ, Gardner EM, et al. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother 2011;66:240-50
46. Myers GM, Mayer KH. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. AIDS Patient Care STDS 2011;25:63-71
47. Jhaveri MA, Mawad HW, Thornton AC, et al. Tenofovir-associated severe bone pain: i cannot walk! J Int Assoc Physicians AIDS Care. 2010;9:328-34
48. Vigano A, Zuccotti GV, Martelli L, et al. Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study. Clin Drug Investig 2007;27:573-81 (Pubitemid 47124099)
49. Calmy A, Fux CA, Norris R, et al. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis 2009;200:1746-54
50. Kohler JJ, Hosseini SH, Green E, et al. Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab Invest 2011;91:852-8
51. Hurt CB, Eron JJ Jr, Cohen MS. Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis 2011;53:1265-70
52. Wolf K, Walter H, Beerenwinkel N, et al. Tenofovir resistance and resensitization. Antimicrob Agents Chemother 2003;47:3478-84 (Pubitemid 37345707)
53. Cheung PK, Wynhoven B, Harrigan PR. Which HIV-1 drug resistance mutations are common in clinical practice? AIDS Rev 2004;6:107-16 (Pubitemid 39149449)
54. White KL, Chen JM, Margot NA, et al. Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations. Antimicrob Agents Chemother 2004;48:992-1003 (Pubitemid 38280354)
55. Das K, Bandwar RP, White KL, et al. Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance. J Biol Chem 2009;284:35092-100
56. Sigal A, Kim JT, Balazs AB, et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 2011;477:95-8
57. Dolling D, Phillips A, Delpech V, on behalf of the UK HIV Drug Resistance Database and the UK Collaborative HIV Cohort (UK CHIC) Study. Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men. HIV Med 2011;doi: 10.1111/j.1468-1293.2011.00968.x.
58. Hachiya A, Kodama EN, Schuckmann MM, et al. K70Q adds high-level tenofovir resistance to "Q151M complex" HIV reverse transcriptase through the enhanced discrimination mechanism. PLoS One 2011;6:e16242
59. Microbicide Trials Network. MTN-003 Available from: http://www. mtnstopshiv. org/about/hiv-aids
60. NIH News: NIH discontinues Tenofovir vaginal gel in 'VOICE' HIV prevention study. November 25, 2011. Available from: http://www.nih.gov/news/ health/nov2011/niaid-25.htm
61. NIH News: NIH Modifies 'VOICE' HIV prevention study in women: Oral Tenofovir discontinued in clinical trial. Available from: http://www.niaid.nih. gov/news/newsreleases/2011/Pages/VOICEmodified.aspx
62. Patterson KB, Prince HA, Kraft E, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 2011;3:112re4
63. Vig R, Venkatachalam TK, Uckun FM. D4T-5'-[p-bromophenyl methoxyalaninyl phosphate] as a potent and non-toxic anti-human immunodeficiency virus agent. Antivir Chem Chemother 1998;9:445-8 (Pubitemid 28446027)
64. Uckun FM, Pendergrass S, Venkatachalam TK, et al. Stampidine is a potent inhibitor of zidovudine and nucleoside analog reverse transcriptase inhibitor-resistant primary clinical HIV-1 isolates with thymidine analog mutations. Antimicrob Agents Chemother 2002;46:3613-16 (Pubitemid 35192934)
65. Venkatachalam TK, Tai HL, Vig R, et al. Enhancing effects of a mono-bromo substitution at the para position of the phenyl moiety on the metabolism and anti-HIV activity of d4T-phenyl methoxyalaninyl phosphate derivatives. Bioorg Med Chem Lett 1998;8:3121-6 (Pubitemid 28551632)
66. Zhang H, Dornadula G, Beumont M, et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 1998;339:1803-9 (Pubitemid 29005784)
67. D'Cruz OJ, Venkatachalam TK, Uckun FM. Thymidine kinase-independent intracellular delivery of bioactive nucleotides by aryl phosphate derivatives of bromo-methoxy zidovudine (compounds WHI-05 and WHI-07) in normal human female genital tract epithelial cells and sperm. Biol Reprod 2001;64:51-9 (Pubitemid 32044612)
68. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006;20:13-23
69. Paraskevis D, Pybus O, Magiorkinis G, SPREAD Programme. Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. Retrovirology 2009;6:49
70. Uckun FM, Pendergrass S, Qazi S, Venkatachalam TK. In vitro activity of stampidine against primary clinical HIV isolates. Arzneimittelforschung 2004;54:69-77 (Pubitemid 38147098)
71. Uckun FM, Venkatachalam TK, Qazi S. Potency of Stampidine against multi-nucleoside reverse transcriptase inhibitor resistant human immunodeficiency viruses. Arzneimittelforschung 2006;56:193-203
72. D'Cruz OJ, Uckun FM. Microbicides for multidrug-resistant and multitropic HIV-1. [Review]. Curr Opin Investig Drugs 2008;9(2):152-69 (Pubitemid 351206374)
73. Uckun FM, Qazi S, Venkatachalam TK. In vitro anti-HIV potency of Stampidine alone and in combination with standard anti-HIV drugs. Arzneimittelforschung 2005;55:223-31 (Pubitemid 40562613)
74. Peeters M, Esu-Williams E, Vergne L, et al. Predominance of subtype A and G HIV type 1 in Nigeria, with geographical differences in their distribution. AIDS Res Hum Retroviruses 2000;16:315-25 (Pubitemid 30132086)
75. Yirrell DL, Kaleebu P, Morgan D, et al. Inter-and intra-genic intersubtype HIV-1 recombination in rural and semi-urban Uganda. AIDS 2002;16:279-86 (Pubitemid 34118575)
76. Steain MC, Wang B, Dwyer DE, Saksena NK. HIV-1 co-infection, superinfection and recombination. Sex Health 2004;1:239-50
77. Brenner B, Routy JP, Quan Y, Co-Investigators of the Quebec Primary Infection Study. Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS 2004;18:1653-60 (Pubitemid 39095782)
78. Smith DM, Wong JK, Hightower GK, et al. HIV drug resistance acquired through superinfection. AIDS 2005;19:1251-6 (Pubitemid 41224893)
79. Smith DM, Strain MC, Frost SD, et al. Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. Virology 2006;355:1-5 (Pubitemid 44585057)
80. Campbell MS, Gottlieb GS, Hawes SE, et al. HIV-1 superinfection in the antiretroviral therapy era: are seroconcordant sexual partners at risk? PLoS One 2009;4:e5690
81. Moyle GJ, Basar A, Gazzard BG. Frequency of multinucleoside analogue-resistant genotypes observed during antiretroviral therapy. AIDS 2000;14:1292-3 (Pubitemid 30420683)
82. Moyle GJ, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005;191:866-72 (Pubitemid 40349800)
83. Blackard JT, Cohen DE, Mayer KH. Human immunodeficiency virus superinfection and recombination: current state of knowledge and potential clinical consequences. Clin Infect Dis 2002;34:1108-14 (Pubitemid 34289684)
84. Uckun FM. Unmet challenges in HIV therapy and potential of stampidine. Arzneimittelforschung 2006;56:117-20
85. Uckun FM. Stampidine as a novel nucleoside reverse transcriptase inhibit with potent anti-HIV activity. Arzneimittelforschung 2006;56:121-35
86. Chen CL, Venkatachalam TK, Zhu ZH, Uckun FM. In vivo pharmacokinetics and metabolism of anti-HIV agent D4T-5'-[p-bromophenyl methoxyalaninyl phosphate] in mice. Drug Metab Dispos 2001;29:1035-41 (Pubitemid 32605920)
87. Chen CL, Yu G, Venkatachalam T, Uckun FM. Metabolism of stavudine-5'-[p-bromophenyl methoxy alaninyl phosphate], stampidine, in mice, dogs, and cats. Drug Metab Dispos 2002;30:1523-31
88. Uckun FM, Qazi S, Pendergrass S, et al. In vivo toxicity, pharmacokinetics, and anti-HIV activity of stavudine-5'-(pbromo phenyl methoxyalaninyl phosphate) (stampidine) in mice. Antimicrob Agents Chemother 2002;46:3428-36
89. Uckun FM, Chen CL, Lisowski E, et al. Toxicity and pharmacokinetics of stampidine in mice and rats. Arzneimittelforschung 2003;53:357-67 (Pubitemid 36609830)
90. Uckun FM, Waurzyniak B, Tibbles H, et al. In vivo pharmacokinetics and toxicity profile of the anti-HIV agent stampidine in dogs and feline immunodeficiency virus-infected cats. Arzneimittelforschung 2006;56:176-92
91. Uckun FM, Chen CL, Samuel P, et al. In vivo antiretroviral activity of stampidine in chronically FIV-infected cats. Antimicrob Agents Chemother 2003;47:1233-40 (Pubitemid 36368580)
92. D'Cruz OJ, Erbeck D, Uckun FM. Developmental safety profile of the anti-HIV agent stampidine in rabbits. Arzneimittelforschung 2006;56:159-66
93. DuMez D, Venkatachalam TK, Uckun FM. Large-scale synthesis and formulation of GMP-grade stampidine, a new anti-HIV agent. Arzneimittelforschung 2006;56:136-51
94. Uckun FM, DuMez D, Qazi S, et al. Anti-retroviral activity of GMP-grade stampidine against genotypically and phenotypically nucleoside reverse transcriptase inhibitor resistant recombinant human immunodeficiency virus. An in vitro study. Arzneimittelforschung 2007;57:112-21 (Pubitemid 46383952)
95. Cahn P, Rolon MJ, Gun AM, et al. Preclinical and first-in-human phase I clinical evaluation of stampidine, a potent anti-HIV pharmaceutical drug candidate. J AIDS Clin Res 2012;3:1 In press